Mayo Clinic researchers identify drug resistance factors for advanced prostate cancer

In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.

Lack of diversity in genomic databases may affect therapy selection for minority groups

Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.

The researchers investigated the use of genomic databases and found that tumor mutation burden was significantly inflated in Black patients compared to White patients.

As a result of the study, clinicians who are using public genomic databases need to be aware of the potential for inflated tumor mutation burden values and how that may affect therapy selection and outcomes, especially for patients from underrepresented groups.

Mayo scientists develop mathematical index to distinguish healthy microbiome from diseased

What causes some people to develop chronic diseases such as rheumatoid arthritis, cancer and metabolic syndrome while others stay healthy? A major clue could be found in their gut microbiome — the trillions of microbes living inside the digestive system that regulate various bodily functions.